NVS-CRF38 is primarily utilized in pharmacological research, particularly in the study of stress-related disorders and anxiety. It functions as a selective antagonist for corticotropin-releasing factor (CRF) receptors, which play a significant role in the body's response to stress. By blocking these receptors, NVS-CRF38 helps researchers understand the mechanisms underlying stress and anxiety, paving the way for the development of novel therapeutic agents. Its application extends to preclinical studies where it is used to evaluate the efficacy of potential treatments for conditions such as depression, post-traumatic stress disorder (PTSD), and other stress-induced psychiatric disorders. Additionally, NVS-CRF38 is employed in behavioral studies to assess its impact on stress-related behaviors in animal models, providing valuable insights into the neurobiological pathways involved in stress regulation.